6446
Stay up-to-date on topics of Internal Medicine including educational cases, guidelines, important research findings. Admin: Amir Ali Sohrabpour MD Former Provost & Assoc Prof of Gastro/Hepato @ TUMS 🇮🇷 Https://zil.ink/aasohrabpour
💢 Debunking the 3,500-Calorie-per-Pound Rule
https://nutritionfacts.org/blog/debunking-the-3500-calorie-per-pound-rule/
🆔 @internalmed
.
💢 FDA warns adults with diabetes about counterfeit semaglutide products
https://www.healio.com/news/endocrinology/20231228/fda-warns-adults-with-diabetes-about-counterfeit-semaglutide-products
🆔 @internalmed
.
💢 The implications of SELECT on CVD prevention in high-risk patients with obesity
https://www.healio.com/news/cardiology/20231229/at-issue-the-implications-of-select-on-cvd-prevention-in-highrisk-patients-with-obesity
🆔 @internalmed
.
💢 Dulaglutide reduces risk for weight gain among women who quit smoking
https://www.healio.com/news/primary-care/20231227/dulaglutide-reduces-risk-for-weight-gain-among-women-who-quit-
🆔 @internalmed
.
💢 Postpartum Depression
https://edhub.ama-assn.org/jn-learning/audio-player/18841900
🆔 @internalmed
.
💢 Weight Loss Drug Zepbound Now Available in US Pharmacies
Zepbound (tirzepatide) is now available for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity); or 27 kg/m2 or greater (overweight) in the presence of at least 1 weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).
Zepbound contains tirzepatide, a glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. The approval was based on data from two 72-week, double-blind, placebo-controlled, phase 3 trials: SURMOUNT-1 (ClinicalTrials.gov Identifier: NCT04184622) and SURMOUNT-2 (ClinicalTrials.gov Identifier: NCT04657003). Findings from both studies showed significant reductions in body weight among patients treated with Zepbound compared with placebo.
🆔 @GIJournalClub
.
💢 Blood pressure remains largest contributor to global CVD; mortality on the rise
Global CV mortality and the prevalence of important cardiometabolic risk factors increased through 2022, with high BP remaining the strongest contributor, according to the 2023 update to the Global Burden of Disease special report on CVD.
👇
https://www.healio.com/news/cardiology/20231211/bp-remains-largest-contributor-to-global-cvd-mortality-on-the-rise
🆔 @internalmed
.
💢 Three-quarters of patients in RA remission flare within 3 years of TNF inhibitor taper
Meanwhile, just 15% of patients in RA remission who remained on stable TNF inhibition demonstrated flare during the same time period.
👇
https://www.healio.com/news/rheumatology/20231219/threequarters-of-patients-in-ra-remission-flare-within-3-years-of-tnf-inhibitor-taper
🆔 @internalmed
.
💢 The First Positive Randomized Trial for Long COVID
Last week researchers in Hong Kong published a randomized, double-blind, placebo-controlled trial of a gut microbiome intervention in 463 participants with Long Covid. This “synbiotic” preparation of combined pre- and probiotics, consisted of a “micro-encapsulated lyophilised powder containing 20 billion colony-forming units of three bacterial strains, B adolescentis, Bifidobacterium bifidum, and Bifidobacterium longum with three prebiotic compounds including galacto-oligosaccharides, xylo-oligosaccharides, and resistant dextrin.” It provided symptomatic relief at 6 months across most of the common and important symptoms of Long Covid.
The benefit derived was incomplete, since the alleviation of symptoms (the primary endpoint) was not accompanied by improvement in overall quality of life as assessed subjectively. So even if this welcome positive trial paves the way for gut microbiome manipulation, it is unlikely to be enough on its own.
🆔 @internalmed
.
🔥
💢 Vitamin D supplements do not prevent bone fractures in children
A major clinical trial led by Queen Mary University of London and the Harvard T.H. Chan School of Public Health has found that vitamin D supplements do not increase bone strength or prevent bone fractures in children with vitamin D deficiency. The findings challenge widely held perceptions relating to the effects of vitamin D on bone health.
Clinical trials designed to test whether vitamin D supplements can prevent bone fractures in children have not previously been conducted.
The study, published in Lancet Diabetes & Endocrinology, is the largest randomised controlled trial of vitamin D supplementation ever conducted in children. Over the course of three years, 8,851 schoolchildren aged 6-13 living in Mongolia received a weekly oral dose of vitamin D supplementation.
95.5% of participants had vitamin D deficiency at baseline, and study supplements were highly effective in boosting vitamin D levels into the normal range.
However, they had no effect on fracture risk or on bone strength, measured in a subset of 1,438 participants using quantitative ultrasound.
The trial findings are likely to prompt scientists, doctors and public health specialists to re-consider the effects of vitamin D supplements on bone health.
The absence of any effect of sustained, generous vitamin D supplementation on fracture risk or bone strength in vitamin D deficient children is striking. In adults, vitamin D supplementation works best for fracture prevention when calcium is given at the same time -- so the fact that we did not offer calcium alongside vitamin D to trial participants may explain the null findings from this study.
It is also important to note that children who were found to have rickets during screening for the trial were excluded from participation, as it would not have been ethical to offer them placebo (dummy medication).
Thus, our findings only have relevance for children with low vitamin D status who have not developed bone complications. The importance of adequate vitamin D intake for prevention of rickets should not be ignored.
👉 Full-Text
🆔 @internalmed
.
💢 Semaglutide and Cardiovascular Outcomes in Obesity
The GLP-1 receptor agonist semaglutide can reduce adverse cardiovascular events in patients with diabetes. Whether this effect extends to patients with overweight or obesity, but without diabetes, is unknown.
New research findings are summarized in a short video.
To see the full article, follow this link: https://nej.md/465pj91
https://youtu.be/DTOcV8uFZyw?si=M6TmFn0zppdpHP_u
🆔 @internalmed
.
💢 Higher salt intake associated with increased risk for type 2 diabetes
https://www.healio.com/news/primary-care/20231116/higher-salt-intake-associated-with-increased-risk-for-type-2-diabetes
🆔 t.me/internalmed
.
💢 Stem cell injections improve pain, function in knee osteoarthritis
https://www.healio.com/news/rheumatology/20231116/stem-cell-injections-improve-pain-function-in-knee-osteoarthritis
🆔 t.me/internalmed
.
📍عصرانه این هفته:
آنافیلاکسی
📍با حضور:
آقای دکتر مهدی مومنی
متخصص طب اورژانس
هیات علمی دانشگاه علوم پزشکی تهران
🗓 جمعه ۲۶ آبان
⏰ ساعت پنج و نیم عصر
🔗 لینک برنامه عصرانه
👈 ثبت در تقویم گوگل
آنافیلاکسی (واکنش آلرژیک شدید و خطرناک) یک اورژانس پزشکی است. برخورد با آنافیلاکسی را همه باید بلد باشند و ندانستن اقدامات لازم، اصلا توجیه پذیر نیست. بنابراین این پیام را برای همه دوستان کادر درمان فوروارد کنید و از آنها بخواهید در این عصرانه شرکت کنند.
#آگاهتر_سالمتر
#عصرانه
#بارش
🌧 بارش، گروهی برای آموزش
.
Practical Guide to Glucocorticoid Induced Hyperglycaemia and Diabetes
Читать полностью…
💢 Dulaglutide reduces risk for weight gain among women who quit smoking
https://www.healio.com/news/primary-care/20231227/dulaglutide-reduces-risk-for-weight-gain-among-women-who-quit-smoking
🆔 @internalmed
.
International Evidence-based Guideline for the assessment and management of polycystic ovary syndrome 2023
Читать полностью…
📍عصرانه این هفته:
آشنایی با مکمل ها
📍با حضور:
دکتر ریحانه صبوریان
دکترای داروسازی
دستیار تخصصی کنترل دارو
🗓 جمعه هشتم دی ماه
⏰ ساعت پنج و نیم عصر
مصرف مکمل های معدنی یا همان مینرال ها، در بین مردم شایع شده و حتی برخی همکاران هم توصیه به مصرف آنها می کنند. نکته مهمی که باید به آن توجه کرد این است که آیا واقعا این محصولات، ضروری هستند و توصیه به استفاده یا عدم استفاده از آنها باید بر چه اساس باش؟ و در واقع مصرف این مکمل ها؛ تحمیل هزینه به بیمار است یا راه حل درمان بیماری آنها؟ در این عصرانه به این موضوعات خواهیم پرداخت و البته بیشتر بر مکمل های آهن و کلسیم تمرکز خواهیم کرد.
🔗 لینک برنامه عصرانه
👈 در تقویم گوگل ثبت کنید
برنامه به صورت لایو در اینستاگرام هم پخش خواهد شد،
اما توصیه ما فعلا شرکت از طریق Google meet است.
شرکت برای عموم آزاد است.
🔥🔥در پادکست عصرانه صوت عصرانه های قبلی را گوش کنید🔥🔥
این پست را برای هر کسی که سلامتیاش برای شما مهم است ارسال کنید.
#آگاهتر_سالمتر
#عصرانه
#بارش
🌧 بارش، گروهی برای آموزش
.
💢 FDA Clears Mosie Baby Kit for At-Home Intravaginal Insemination
The Food and Drug Administration (FDA) has cleared the Mosie Baby Kit for over-the-counter (OTC) home use by individuals who have been unable to conceive through intercourse or choose not to conceive through intercourse, for semen collection and the delivery of semen or donor sperm to the vaginal canal.
“To date, we’re very proud to share that Mosie Baby has helped more than 100,000 families inseminate from the comfort of their own home. We are now thrilled to offer our device as an FDA reviewed option for families looking to inseminate at home.”
The Mosie Baby At-Home Insemination Kit is available for $129.99 at mosiebaby.com, CVS.com (or CVS stores), Walmart.com and optumstore.com. The kit is expected to launch in additional stores in 2024, according to the company.
🆔 @hr1ghadam
.
💢 A Deficient Diagnosis | NEJM
https://www.youtube.com/watch?v=4TDa2M0qxjA
🆔 @internalmed
.
بر اساس مطالعه ای که در شماره 12 دسامبر JAMA منتشر شد، در زنان باردار مبتلا به دیابت نوع 2، افزودن متفورمین به انسولین بر پیامدهای نامطلوب نوزادی تأثیر نمی گذارد.
در این کارآزمایی بالینی تصادفی شده که شامل خانمهای باردار 18 تا 45 ساله مبتلا به دیابت نوع 2 بود، اثر متفورمین اضافه شده به انسولین مورد بررسی قرار گرفت.
شرکتکنندگان تحت درمان با انسولین قرار گرفتند و متفورمین 1000 میلیگرم یا دارونما (397 در هر گروه) دریافت کردند.
پیامد نامطلوب برای نوزاد به ترتیب در 71 و 74 درصد از شرکتکنندگان در گروههای متفورمین و دارونما رخ داد که تفاوت معناداری نداشت.
در هر دو گروه، شایعترین رویدادهای رخ داده شامل زایمان زودرس، هیپوگلیسمی نوزادی و تولد نوزاد بزرگ برای سن حاملگی بود.
🆔 @internalmed
.
💢 What is the diagnostic approach to acute exacerbations of COPD?
https://emorymedicine.wordpress.com/2023/12/19/midtown-morning-report-what-is-the-diagnostic-approach-to-acute-exacerbations-of-copd/
🆔 @internalmed
.
💢 Expert opinion on bleeding risk from invasive procedures in cirrhosis
This position paper surveyed 52 experts on bleeding risk associated with 80 procedures
Out of 80 procedures, a consensus opinion was reached for 52 procedures. 17 procedures were classified as high-risk and 35 as low-risk.
Low-risk procedures were primarily “diagnostic” procedures
Lowest acceptable platelet counts for low-risk, and high-risk procedures were 30 and 50x109/L, respectively.
INR should not be taken into account before performing low-risk and high-risk procedures
👉 Full-Text
🆔 @GIJournalClub
.
📍عصرانه این هفته:
رضایت شخصی
📍با حضور:
دکتر آرش عکاظی
متخصص پزشکی قانونی
عضو هیات علمی دانشگاه علوم پزشکی تهران
🗓 جمعه یکم دی ماه
⏰ ساعت پنج و نیم عصر
🔗 لینک برنامه عصرانه
👈 ثبت در تقویم گوگل
برنامه به صورت لایو در اینستاگرام هم پخش خواهد شد،
اما توصیه ما فعلا شرکت از طریق Google meet است.
شرکت برای عموم آزاد است.
رضایت شخصی یا "ترخیص با رضایت شخصی" به معنای انتخاب بیمار برای خروج از بیمارستان قبل از اعلام مرخصی توسط پزشک معالج است. این مفهوم نشان دهنده حق بیماران است که بتوانند با آگاهی کامل و بدون فشار از مراقبت تیم درمان و از بیمارستان خارج شوند. این موضوع میتواند یکی از حقوق بیماران شمرده شود. آگاهی از نکات ظریف مرتبط با رضایت شخصی، برای تمامی همکاران کادر درمان ضروری است.
🔥🔥در پادکست عصرانه صوت عصرانه های قبلی را گوش کنید🔥🔥
این پست را برای هر کسی که سلامتیاش برای شما مهم است ارسال کنید.
#آگاهتر_سالمتر
#عصرانه
#بارش
🌧 بارش، گروهی برای آموزش
.
💢 Therapy choice in rheumatoid arthritis does not impact serious infection risk
https://www.healio.com/news/rheumatology/20231213/therapy-choice-in-rheumatoid-arthritis-does-not-impact-serious-infection-risk
🆔 @internalmed
.
💢 Women with prediabetes may benefit from earlier intervention to prevent CVD
https://www.healio.com/news/endocrinology/20231212/women-with-prediabetes-may-benefit-from-earlier-intervention-to-prevent-cvd
🆔 @internalmed
.
💢 GLP-1 Drugs Like Ozempic and Wegovy Can Help Reduce Heart Attack Risk
https://www.healthline.com/health-news/semaglutide-reduces-heart-attack-stroke-risk
🆔 t.me/internalmed
.
💢 Mean HbA1c declined for people with type 1 diabetes from 2016 to 2022
https://www.healio.com/news/endocrinology/20231110/mean-hba1c-declines-for-people-with-type-1-diabetes-from-2016-to-2022
🆔 t.me/internalmed
.